
Medico Remedies Ltd Upgraded to Hold as Technicals Improve and Financials Strengthen
2026-06-17 08:34:50Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 16 June 2026. This change reflects a nuanced improvement across technical indicators, financial performance, valuation metrics, and overall quality assessments, signalling a cautious but positive outlook for investors.
Read full news article
Medico Remedies Ltd Downgraded to Sell Amid Technical Weakness and Growth Concerns
2026-06-12 08:19:14Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 11 June 2026. This shift reflects a combination of deteriorating technical indicators, tempered long-term growth prospects, and valuation concerns despite recent positive quarterly financial results.
Read full news article
Medico Remedies Ltd is Rated Hold by MarketsMOJO
2026-06-01 10:10:51Medico Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 June 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.
Read full news articleAre Medico Remedies Ltd latest results good or bad?
2026-05-22 19:28:43Medico Remedies Ltd's latest financial results for the quarter ending March 2026 present a mixed operational narrative. The company reported a record net sales figure of ₹56.81 crores, reflecting a year-on-year growth of 37.55% compared to ₹41.30 crores in the same quarter last year. This indicates strong demand and sales momentum. Additionally, the net profit after tax surged to ₹5.86 crores, marking a year-on-year increase of 35.02%, which is a notable achievement. However, when examining the sequential performance, the results reveal some challenges. Revenue declined by 3.19% from the previous quarter's ₹58.68 crores, suggesting potential fluctuations in order execution or seasonal demand variations. Furthermore, the operating margin contracted to 12.59%, down from 16.15% in the same quarter last year, indicating volatility in profitability. The company's return on equity remains robust at 17.35%, show...
Read full news article
Medico Remedies Q4 FY26: Strong Profit Surge Masks Margin Volatility Concerns
2026-05-22 09:54:37Medico Remedies Ltd., a micro-cap pharmaceutical manufacturer, delivered a robust performance in Q4 FY26 (January-March 2026) with net profit surging 35.02% year-on-year to ₹5.86 crores, marking the company's strongest quarterly earnings to date. However, the quarter-on-quarter decline of 3.19% in revenue and persistent margin volatility have raised questions about the sustainability of this growth trajectory for the ₹389.69 crore market capitalisation company.
Read full news article
Medico Remedies Ltd is Rated Hold by MarketsMOJO
2026-05-21 10:10:58Medico Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 21 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read full news article
Medico Remedies Ltd is Rated Hold by MarketsMOJO
2026-05-10 10:10:37Medico Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 May 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
Medico Remedies Ltd Downgraded to Sell Amid Bearish Technicals and Underperformance
2026-04-29 08:24:39Medico Remedies Ltd has seen its investment rating downgraded from Hold to Sell as of 28 Apr 2026, driven primarily by deteriorating technical indicators despite some positive financial trends. The micro-cap pharmaceutical company’s current Mojo Score stands at 47.0, reflecting a cautious outlook amid mixed signals across quality, valuation, financial trend, and technical parameters.
Read full news article
Medico Remedies Ltd Upgraded to Hold as Technicals Improve and Financials Strengthen
2026-04-23 08:23:40Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 22 April 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, financial trends, and overall company quality, signalling a cautious but positive outlook for investors amid mixed long-term performance.
Read full news articleCorporate Actions
No Upcoming Board Meetings
No Dividend history available
Medico Remedies Ltd has announced 2:10 stock split, ex-date: 16 Mar 23
Medico Remedies Ltd has announced 3:1 bonus issue, ex-date: 16 Nov 21
No Rights history available






